Lantheus closes strategic collaboration & license agreements with POINT Biopharma for PNT-2002 and PNT-2003

Lantheus Holdings, Inc.

Paid $250M upfront for PNT-2002 (prostate cancer therapy); $10M upfront for PNT-2003 (neuroendocrine tumor therapy).
Potential regulatory milestones up to $281M (PNT-2002) and $34.5M (PNT-2003); sales milestones up to $1.28B and $275M, respectively.
PNT-2002 royalties: 20% after $500M cumulative gross profit; PNT-2003 royalties: 15% of net sales.
Agreements became effective Dec 20, 2022, after HSR waiting period expired.
Lantheus will develop and commercialize both candidates worldwide except certain Asian countries.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.